A multitude of small molecule inhibitors of the BET family proteins have been employed to enhance the synergy of tumor chemotherapy, and these studies have demonstrated that the inhibition of BET proteins can indeed sensitize tumors to chemotherapy and extend survival in mice.[46, 47, 48] However, these small molecule inhibitors are more prone to off‐target effects and systemic toxicity due to the necessity for higher doses. Here, DNER is linked to neoplasm.